Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 131

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 131
---
,147 Operating lease right-of-use liabilities483,789 419,234 Deferred tax liabilities106,960 191,349 Other long-term liabilities195,212 223,191 Total liabilities4,020,267 4,536,003 Commitments and contingencies (Notes 2, 11, 13, and 18)Redeemable noncontrolling interests41,126 56,722 Equity:  Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding— — Common stock, $0.01 par value; 120,000 shares authorized; 51,141 shares issued and outstanding as of December 28, 2024 and 51,338 shares issued and outstanding as of December 30, 2023511 513 Additional paid-in capital1,966,237 1,905,578 Retained earnings1,812,100 1,887,218 Treasury stock, at cost, zero shares as of December 28, 2024 and December 30, 2023— — Accumulated other comprehensive loss(317,345)(196,427)Total Charles River Laboratories International, Inc. equity3,461,503 3,596,882 Nonredeemable noncontrolling interest5,449 5,394 Total equity3,466,952 3,602,276 Total liabilities, redeemable noncontrolling interests and equity$7,528,345 $8,195,001 See Notes to Consolidated Financial Statements.

61

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)

 Fiscal Year 202420232022Cash flows relating to operating activities   Net income$25,291 $480,370 $492,608 Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization361,741 314,124 303,870 Goodwill impairment215,000 — — Long-lived asset impairments51,825 41,911 5,816 Stock-based compensation69,891 72,048 73,617 Deferred income taxes (67,428)(50,903)(35,884)Write down of inventories46,992 6,290 5,973 (Gain) loss